In August, 2004, NY-state based Enhance Biotech (PK:EBOI), a developer of a portfolio of products focused on lifestyle drugs, signed a definitive merger agreement with Ardent Pharmaceuticals, a developer of delta receptor compounds. Formerly known as Delta Pharmaceuticals, Inc. Ardent Pharmaceuticals, Inc. is a privately held biotechnology company applying its scientific expertise to the development of novel therapeutics for a wide range of indications where current treatments are unavailable or inadequate. Leveraging its proprietary delta receptor technology, the Company has developed clinical candidates for its lead area of pain management, with two products in Phase II trials. Ardent also has an extensive research and development pipeline that includes preclinical candidates for urinary incontinence, depression, cardioprotection, glaucoma and other areas.
